Investors

Rights Issue

Preliminary time table

1 December 2020 - Last trading day in NextCell's shares, including the right to receive subscription rights
‍
‍2 December 2020 - First trading day in NextCell's shares excluding the right to receive subscription rights
‍
‍3 December 2020 - Record date for obtaining subscription rights
‍
‍3 December 2020 - Beräknad dag för offentliggörande av prospekt avseende Företrädesemissionen
‍
‍7 December – 21 December 2020 - Subscription period for the Rights Issue
‍
‍7 December – 17 December 2020 - Subscription rights trading on the Nasdaq First North Growth Market
‍
‍7 December – around week 1, 2021 - Trade with paid subscription “BTA”Around 23 December 2020 - Estimated date for publication of the outcome of the Rights Issue

Here you will find the prospectus and subscription notes for the Rights Issue

Financial calendar

Q1 report 2023

January 26, 2023

Q2 report 2023

April 27, 2023

Q3 report 2023

July 27, 2023

Year End Report 2023

October 26, 2023

Annual General Meeting

November 30, 2023

Financial reports

2028

No reports published yet.

2027

No reports published yet.

2026

No reports published yet.

2025

No reports published yet.

2024

No reports published yet.

Corporate Governance

Auditor

‍Öhrlings PricewaterhouseCoopers AB (PwC)
Torsgatan 21, 113 97 Stockholm

PwC has been the company's auditor since 2014. The primary auditor, since 2018, is Johan Engstam. Johan Engstam is an Authorized Public Accountant and a member of FAR, the institute for the accountancy profession in Sweden.

Articles Of Association

Download

Annual Meetings

Annual Meeting 2022

Fullmaktsformulär årsstämma 2022

24/11/2022

Kallelse till årsstämma 2022

24/11/2022

Annual Meeting 2021

Kallelse till årsstämma 2021

24/11/2021

Fullmaktsformulär

24/11/2021

Annual Meeting 2020

Fullmaktsformulär

24/11/2020

Kallelse till årsstämma 2020

24/11/2020

Kommuniké från årsstämma

24/11/2020

Annual Meeting 2019

Power of attorney – Annual general meeting 2019

5/12/2019

Notice to attend Annual General Meeting 2019

5/12/2019

Fullständiga handlingar inför årsstämma

5/12/2019

Annual Meeting 2018

Power of attorney – Annual general meeting 2018

5/12/2018

Notice to attend Annual General Meeting 2018

5/12/2018

Kommuniké från årsstämma 2018

5/12/2018

Full list of resolutions ahead of Annual General Meeting 2018

5/12/2018

Annual report (audited)

5/12/2018

Annual Meeting 2017

Proxy form for Annual General Meeting of NextCell Pharma AB on 24 February 2017 extraordinary

24/2/2017

Notice to attend Annual General Meeting of NextCell Pharma AB on 24 February 2017

24/2/2017

Full list of resolutions ahead of Annual General Meeting of NextCell Pharma AB on 24 February 2017

24/2/2017

Power of attorney – Annual general meeting 2017

5/12/2017

Kommuniké från årsstämma 2017

5/12/2017

Certified Adviser

FNCA Sweden AB

Address: Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm

Phone: +46(0)8-528 00 399

Mail: info@fnca.se

The Share

Shareholders

List of 10 largest shareholders as of December 31, 2022:

‍‍

Owner

Percentage

Diamyd Medical AB

4,283,861

12.5

Försäkringsbolaget Avanza Pension

3,547,460

10.3

Anders Essen-Möller*

2,526,909

7.4

Ålandsbanken i ägares ställe

1,223,243

3.6

Christer Janssson

1,003,667

2.9

Pabros AB

847,452

2.5

Nordnet Pensionsförsäkring AB

699,941

2.0

Konstruktions och Försäljningsaktiebolaget KFAB

650,000

1.9

Nordea LIvförsäkring Sverige AB

590,619

1.7

Filip Wirefors

497,000

1.4

Total

15,870,152

46.2

* In addition to Chairman of the Board, Anders Essen-Möller's directly registered holdings, this item includes holdings of 4.09 percent managed by Avanza Pension.

Trading information

NextCell Pharma AB is listed on the Nasdaq First North Growth Market since July 2020. The stock is traded under the ticker “NXTCL”. ISIN Code: SE0009723125.

The current share price is available on Nasdaq First North website:

Nasdaq OMX Nordic

Dividend policy

NextCell has to date paid no dividends to its shareholders. The company is in a development phase, and any surplus is primarily planned for reinvestment in the company’s development.